127
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Corneal Epithelial Dendritic Cells: An Objective Indicator for Ocular Surface Inflammation in Patients with Obstructive Meibomian Gland Dysfunction?

, MD, , MD, , MD, , PhD, , MD, , MD, , MD, , MD, , MD, , MD & , MD, PhD show all
Pages 79-88 | Received 06 Sep 2022, Accepted 02 Dec 2022, Published online: 09 Jan 2023

References

  • Nelson JD, Shimazaki J, Benitez-Del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):1930–1937. doi:10.1167/iovs.10-6997b.
  • Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003.
  • Rhee MK, Mah FS. Inflammation in dry eye disease: how do we break the cycle? Ophthalmology. 2017;124(11s):S14–s19. doi:10.1016/j.ophtha.2017.08.029.
  • Lee H, Min K, Kim EK, Kim TI. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol. 2012;154(6):949–957.e941. doi:10.1016/j.ajo.2012.06.009.
  • Landsend ECS, Utheim ØA, Pedersen HR, et al. The level of inflammatory tear cytokines is elevated in congenital aniridia and associated with meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2018;59(5):2197–2204. doi:10.1167/iovs.18-24027.
  • Suzuki T. Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation. Invest Ophthalmol Vis Sci. 2018;59(14):Des94–des101. doi:10.1167/iovs.17-23345.
  • Oh J, Shin JS. The role of dendritic cells in central tolerance. Immune Netw. 2015;15(3):111–120. doi:10.4110/in.2015.15.3.111.
  • Mastropasqua L, Nubile M, Lanzini M, et al. Epithelial dendritic cell distribution in normal and inflamed human cornea: in vivo confocal microscopy study. Am J Ophthalmol. 2006;142(5):736–744. doi:10.1016/j.ajo.2006.06.057.
  • Dana MR. Corneal antigen-presenting cells: diversity, plasticity, and disguise: the Cogan lecture. Invest Ophthalmol Vis Sci. 2004;45(3):722–727; 721. doi:10.1167/iovs.03-0803.
  • Hwang J, Dermer H, Galor A. Can in vivo confocal microscopy differentiate between sub-types of dry eye disease? A review. Clin Exp Ophthalmol. 2021;49(4):373–387. doi:10.1111/ceo.13924.
  • Xu J, Chen P, Yu C, Liu Y, Hu S, Di G. In vivo confocal microscopic evaluation of corneal dendritic cell density and subbasal nerve parameters in dry eye patients: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:578233. doi:10.3389/fmed.2021.578233.
  • Qazi Y, Kheirkhah A, Blackie C, et al. In vivo detection of clinically non-apparent ocular surface inflammation in patients with meibomian gland dysfunction-associated refractory dry eye symptoms: a pilot study. Eye (Lond). 2015;29(8):1099–1110. doi:10.1038/eye.2015.103.
  • Fu J, Chou Y, Hao R, Jiang X, Liu Y, Li X. Evaluation of ocular surface impairment in meibomian gland dysfunction of varying severity using a comprehensive grading scale. Medicine (Baltimore). 2019;98(31):e16547. doi:10.1097/md.0000000000016547.
  • Zhao H, Li Q, Ye M, Yu J. Tear luminex analysis in dry eye patients. Med Sci Monit. 2018;24:7595–7602. doi:10.12659/msm.912010.
  • Aragona P, Aguennouz M, Rania L, et al. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology. 2015;122(1):62–71. doi:10.1016/j.ophtha.2014.07.048.
  • Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim TI. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014;158(6):1172–1183.e1171. doi:10.1016/j.ajo.2014.08.015.
  • Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006–2049. doi:10.1167/iovs.10-6997f.
  • Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–621. doi:10.1001/archopht.118.5.615.
  • Wong S, Srinivasan S, Murphy PJ, Jones L. Comparison of meibomian gland dropout using two infrared imaging devices. Cont Lens Anterior Eye. 2019;42(3):311–317. doi:10.1016/j.clae.2018.10.014.
  • Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. Clao J. 1995;21:221–232.
  • Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–574. doi:10.1016/j.jtos.2017.05.001.
  • Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650. doi:10.1097/00003226-200310000-00008.
  • Labbé A, Liang Q, Wang Z, et al. Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci. 2013;54(8):5144–5150. doi:10.1167/iovs.13-12370.
  • Aggarwal S, Cavalcanti BM, Regali L, et al. In vivo confocal microscopy shows alterations in nerve density and dendritiform cell density in Fuchs’ endothelial corneal dystrophy. Am J Ophthalmol. 2018;196:136–144. doi:10.1016/j.ajo.2018.08.040.
  • Bron AJ, De Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011.
  • Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. J Mol Diagn. 2003;5(2):73–81. doi:10.1016/s1525-1578(10)60455-2.
  • Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction. Cornea. 2010;29(12):1333–1345. doi:10.1097/ICO.0b013e3181d4f366.
  • Suzuki T. Meibomitis-related keratoconjunctivitis: implications and clinical significance of meibomian gland inflammation. Cornea. 2012;31(Suppl 1):S41–44. doi:10.1097/ICO.0b013e31826a04dd.
  • Li M, Yu Y, Yuan Y, et al. Rete ridges in eyelid margin and inflammatory cytokines in meibomian gland dysfunction associated with dry eye symptom. Curr Eye Res. 2021;46(2):202–209. doi:10.1080/02713683.2020.1788102.
  • Yamaguchi T. Inflammatory response in dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):Des192–des199. doi:10.1167/iovs.17-23651.
  • Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81–90. doi:10.1016/j.ajo.2017.08.021.
  • Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmun. 2017;85:126–140. doi:10.1016/j.jaut.2017.07.012.
  • Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314–1321. doi:10.1038/nm1325.
  • Maruoka S, Inaba M, Ogata N. Activation of dendritic cells in dry eye mouse model. Invest Ophthalmol Vis Sci. 2018;59(8):3269–3277. doi:10.1167/iovs.17-22550.
  • Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165(1):566–572. doi:10.4049/jimmunol.165.1.566.
  • Matundan H, Mott KR, Ghiasi H. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice. J Virol. 2014;88(14):8016–8027. doi:10.1128/jvi.00913-14.
  • Gao Y, Li Z, Hassan N, et al. NK cells are necessary for recovery of corneal CD11c+ dendritic cells after epithelial abrasion injury. J Leukoc Biol. 2013;94(2):343–351. doi:10.1189/jlb.1212633.
  • Levine H, Hwang J, Dermer H, Mehra D, Feuer W, Galor A. Relationships between activated dendritic cells and dry eye symptoms and signs. Ocul Surf. 2021;21:186–192. doi:10.1016/j.jtos.2021.06.001.
  • Na KS, Mok JW, Kim JY, Rho CR, Joo CK. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest Ophthalmol Vis Sci. 2012;53(9):5443–5450. doi:10.1167/iovs.11-9417.
  • Wu X, Chen X, Ma Y, et al. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. Int Ophthalmol. 2020;40(11):3049–3058. doi:10.1007/s10792-020-01489-z.
  • Choi W, Li Z, Oh HJ, et al. Expression of CCR5 and its ligands CCL3, −4, and −5 in the tear film and ocular surface of patients with dry eye disease. Curr Eye Res. 2012;37(1):12–17. doi:10.3109/02713683.2011.622852.
  • Albertsmeyer AC, Kakkassery V, Spurr-Michaud S, Beeks O, Gipson IK. Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells. Exp Eye Res. 2010;90(3):444–451. doi:10.1016/j.exer.2009.12.009.
  • Zhou T, He C, Lai P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv. 2022;8(2):eabj9617. doi:10.1126/sciadv.abj9617.
  • Postnikoff CK, Held K, Viswanath V, Nichols KK. Enhanced closed eye neutrophil degranulation in dry eye disease. Ocul Surf. 2020;18(4):841–851. doi:10.1016/j.jtos.2020.08.011.
  • Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60. doi:10.1016/j.ophtha.2016.09.025.
  • Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol. 2001;2(12):1126–1132. doi:10.1038/ni735.
  • Pinto-Fraga J, Enríquez-De-Salamanca A, Calonge M, et al. Severity, therapeutic, and activity tear biomarkers in dry eye disease: an analysis from a phase III clinical trial. Ocul Surf. 2018;16(3):368–376. doi:10.1016/j.jtos.2018.05.001.
  • Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019;17(1):104–110. doi:10.1016/j.jtos.2018.11.004.
  • Liu R, Ma B, Gao Y, Ma B, Liu Y, Qi H. Tear inflammatory cytokines analysis and clinical correlations in diabetes and nondiabetes with dry eye. Am J Ophthalmol. 2019;200:10–15. doi:10.1016/j.ajo.2018.12.001.
  • Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763–1768. doi:10.1213/ane.0000000000002864.
  • Zheng Q, Xue Y, Zhong X, Li G, Shi W, Wang T. Correlation study between abnormal morphology of meibomian glands and meibum in patients with dry eye disease under in vivo confocal microscopy. Front Med (Lausanne). 2021;8:793338. doi:10.3389/fmed.2021.793338.
  • Aggarwal S, Kheirkhah A, Cavalcanti BM, Cruzat A, Jamali A, Hamrah P. Correlation of corneal immune cell changes with clinical severity in dry eye disease: an in vivo confocal microscopy study. Ocul Surf. 2021;19:183–189. doi:10.1016/j.jtos.2020.05.012.
  • Yu FX, Lee PSY, Yang L, et al. The impact of sensory neuropathy and inflammation on epithelial wound healing in diabetic corneas. Prog Retin Eye Res. 2022;89:101039. doi:10.1016/j.preteyeres.2021.101039.
  • Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300–306. doi:10.1136/bjophthalmol-2015-307415.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.